Twelve sessions were conducted. Results.-Amnesic effect on pain may occur during mobilization. Flexion: 958 active. Pain: 0/10 at rest and walking. Improving the quality of walking with a smooth and not increase walking speed without technical assistance. Resumption of his previous 26 months work after the diagnosis of CRPS-I. Scintigraphy: net regression process CRPS-I detected in his right knee in 2010. Regularization of all households hyperactive. Discussion and conclusion.-This would be for the benefit of nitrous oxide in the mobilization of a stiff joint including CRPS-I through a permitting algofunctional improvement and joints that enabled our patient to return to his previous work. [39; 75] have been treated with continuous intrathecal infusion of baclofene, ziconotide and morphine. Four had a failed back surgery syndrome, 1 peripherical nerve lesion, 1 spine injury, 1 cerebral palsy. Ziconotide has been introduced after the failure of an intrarachidian morphine + baclofene treatment.
Keywords: Chronic pain; Spasticity; Ziconotide; Baclofene; Intrathecal treatment Introduction.-Intrathecal ziconotide has shown its efficiency in chronic resistant pain, we studied the association with baclofene in spastic pain management.
Patients.-Seven patients, 4 female, 3 male, average age 54.3 years old [39; 75] have been treated with continuous intrathecal infusion of baclofene, ziconotide and morphine. Four had a failed back surgery syndrome, 1 peripherical nerve lesion, 1 spine injury, 1 cerebral palsy. Ziconotide has been introduced after the failure of an intrarachidian morphine + baclofene treatment.
Results.-The average decrease of pain intensity after we began the ziconotide treatment was equal to 31 mm on visual analog pain scale, from 68 to 37 mm efter ziconotide introduction. Ziconotide adding had no effect on spasticity which was already efficiently managed by intrathecal baclofene. The average follow-up was 13.3 months [2; 26 months]. Average ziconotide posologies were 3.1 mg per day [1.25; 5.7 mg per day] and 342 mg per day [43; 1800 mg per day] for baclofene. Ziconotide had to be stopped for 3/7 (43%) because of side effects, with a full recovery after treatment interruption. One patient kept auditory hallucination but did not want any posology modification since he was satisfied with the antalgic level. Most of the side effects occurred during the first semester of our using of ziconotide due to a too fast dose increase. The commonest side effects were: nausea, dizziness, ataxia, visual and/or auditory hallucination. No treatment failure has been noticed for two years. Initial treatment administration has to be as low as possible (1 mg per day in our population) in order to obtain antalgic effect without major side effects. A slight increase of doses (+0.3 mg per week) allows pain management without side effects. Conclusion.-Ziconotide in association with intrathecal baclofene is a good way to deal with chronic pain with spasticity. Keywords: Algodystrophy; Pregnancy The algodystrophy is a regional pain syndrome, characterized by complex neurovascular abnormalities. Pregnancy appears through mechanical factors promote dystrophy of the lower limbs. We report a case of bilateral hip dystrophy diagnosed during postpartum. This is a 31-year-old woman, primipara, who presented in the third quarter of pregnancy (35 weeks gestation) mechanical bilateral groin pain with functional impairment. She has consulted in postpartum (4 days after birth). The review noted a limp, functional impairment with a VAS pain 70%. Standard radiographs postpartum showed speckled locoregional demineralization hips. MRI confirmed the diagnosis of CRPS hips. The patient took analgesic treatment with a discharge and rest for 3 months. She has not received bisphosphonates because she breastfeeding. Disease duration was 24 weeks. The evolution was marked by the persistence of residual pain (VAS 20%) without sequelae. The analysis of our results compared to literature, allows to identify the main characteristics of this variety of reflex sympathetic dystrophy: gradual onset in the second or third trimester, location in the hip alone or associated with other locations [1] [2] [3] . MRI is currently the modality of choice for the early and differential diagnosis [1, 3] . The course is generally favorable [3] . Algodystrophy during pregnancy is rare and is often misunderstood. MRI have an important place in the diagnosis of this disease. The safety of bisphosphonates during pregnancy and lactation remains to be demonstrated. References 
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Clinical, ultrasonographic and CT markers for botulinum toxin injections into the piriformis muscle F. Michel * , S. Aubry, P. Decavel, L. Tatu, E. Toussirot, E. Aleton, B. Parratte CHU Jean-Minjoz, boulevard Fleming, 25000 Besançon, France *Corresponding author. E-mail address: fmichel@chu-besancon.fr Keywords: Piriformis muscle; Ultrasound; Botulinum toxin Objective.-The study of the literature concerning the treatment of piriformis muscle syndrome (PMS) to validate the role of botulinum toxin injections performed after failure of medical management and rehabilitation. The few reported series confirm the results significantly superior to placebo injections and even repeated anesthetics and/or corticosteroids. The piriformis muscle belongs to the deep part of the gluteal region where the need for radiological identification. Our team couples the ultrasound with electromyography detection, allowing the latter through an active lateral rotation maneuver (in a subject supine on the healthy side) to optimize the injection site. Ultrasound, with constant technical progress and the development of new sensors, allows very interesting morphological evaluation of the muscle and its relationship with the main sciatic nerve. The objective of this study was to validate the clinical and ultrasonographic markers compared to CT and anatomical data. Patients and methods.-Five patients supported for SMP received botulinum toxin injections under ultrasound and CT with a minimum of 3 months between each injection, the second injection performed because of insufficient improvement of symptoms.
Results.-The clinical markers of projection of the piriformis muscle is defined by a triangle whose base joins the posterior superior iliac spine and the upper part of the inter-gluteal fold, and whose summit is next to the upper pole of the greater trochanter. Ultrasound (abdominal convex probe tone) body muscle is visualized on the lateral edge of the sacrum with a depth of 4.8 cm for the Douleurs (2) : douleurs chroniques et thérapies innovantes / Annals of Physical and Rehabilitation Medicine 56S (2013) e115-e124 e123 superficial surface of the muscle and an average thickness of 1.9 cm (the most Big measured thickness). CT tracking validates the position of the needle in the proximal portion closest to the base of the triangle defined above, as well as anatomical sections performed on cadaver.
Conclusion.-Botulinum toxin injections for difficult sites or deep benefit from advances in imaging and in particular that of ultrasound coupled with electromyography provides an interesting analysis of the injected muscle and secure. This association, even if it requires prior training, is easy to implement, non-radiating and deserves to be released. Results.-It is found on the symptomatic side significantly reduced the thickness (P < 0.001), volume (P < 0.001) and increased fatty infiltration (P < 0.004) of the piriformis muscle compared with the contralateral side considered normal. Univariate analysis in patients treated showed a significant reduction in the thickness (P < 0.001), volume (P < 0.001) and increased fatty infiltration (P < 0.001) treated piriformis muscle injection botulinum toxin, whereas we found no significant difference in these parameters after surgical treatment.
Conclusion.-This study is to our knowledge the first that shows qualitatively and quantitatively the effects of treatment with botulinum toxin in the piriformis muscle atrophy and fatty infiltration. This preliminary study should be correlated with clinical benefit and position control instead of a morphological MRI in the follow-up.
http://dx.doi.org/10.1016/j.rehab.2013.07.253
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